Braingrid Limited Announces Share Consolidation

By Dr. Matthew Watson

TORONTO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Braingrid Limited (CSE: BGRD) (“Braingrid” or the “Company”), is pleased to announce that it is proceeding with a consolidation (the “Consolidation”) of its common shares (“Common Shares”) on the basis of 100 pre-Consolidation Common Shares for one (1) post-Consolidation Common Share. The Consolidation was approved by the shareholders of the Company at the Company’s annual general and special meeting of shareholders held on July 31, 2019.

Here is the original post:
Braingrid Limited Announces Share Consolidation

Related Post


categoriaGlobal News Feed commentoComments Off on Braingrid Limited Announces Share Consolidation | dataNovember 8th, 2020

About...

This author published 5872 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024